What is XCUR's current stock price?

XCUR (Exicure, Inc.) is currently trading at $2.81 with a market cap of $17.9M.

What sector is Exicure, Inc. in?

Exicure, Inc. (XCUR) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is XCUR a good stock to buy?

Analysts have a Buy consensus on XCUR with a price target of $12.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

XCUR Exicure, Inc.

Healthcare

$2.81+1.81%ClosedMarket Cap: $17.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

4.51

P/S

0.00

EV/EBITDA

-1.49

DCF Value

$0.35

FCF Yield

-47.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-63.6%

ROA

-35.2%

ROIC

-36.1%

Financials

View All

Period	Revenue	Net Income	EPS
Q4 null	$0.00	$-2.9M	$—
FY null	$0.00	$-4.9M	$—
Q3 null	$0.00	$-2.4M	$—
Q2 null	$0.00	$-2.6M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$12.00

Target (Median)

$12.00

Target Range

$12.00 - $12.00

1 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Miller Joshofficer: Chief Accounting Officer

SellThu Feb 19

Exicure HiTron Inc.10 percent owner

SellWed Jan 21

Exicure HiTron Inc.10 percent owner

SellTue Jan 20

Exicure HiTron Inc.10 percent owner

SellThu Jan 08

SANGSANGIN INVESTMENT & SECURITIES CO., LTD.10 percent owner

SellWed Dec 10

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

3.62

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

Peers